Reference

Oncologic, endocrine & metabolic

Oncologic, endocrine & metabolic. Anti-obesity drugs: on target for huge market sales. Buttle, Lisa A. (Ashley Publications Ltd., London N6 5QJ, UK). Expert Opinion on Investigational Drugs, 5(12), 1583-1587 (English) 1996 Ashley Publications. CODEN: EOIDER. ISSN: 0967-8298. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review, with 18 refs. Obesity represents a growing health problem; thus, there is potentially a huge market for any successful anti-obesity drug. Dexfenfluramine (Adifax, Redux) is the first of new wave of drugs to be approved for market for the long-term treatment of obesity, despite an assocd. increase risk of primary pulmonary hypertension (PPH). The second, sibutramine (Medaria, Reductil) has recently received an 'approvable letter' from the FDA, only six wk. after being rejected due to concerns over obsd. elevations in blood pressure assocd. with treatment. The clin. trials program for a third, orlistat (Xenical), is nearing completion, with fillings for market applications expected shortly. Only a handful of other compds. have advanced to clin.There are some commonly used reagents with their cas registry numbers 106650-56-0 and 96829-58-2 in this article. trials, yet many more are currently being investigated in preclin. and discovery research, with over 50 companies actively involved in this relatively new area of therapeutic research. While concerns may exist over the side-effects linked with these early therapies and possible cosmetic abuse, this explosion of research interest promises to yield more selective drugs without the assocd. risks, in the near future. .

Treatment of depression secondary to pain using milnacipran and other monoamine reuptake inhibitors

Treatment of depression secondary to pain using milnacipran and other monoamine reuptake inhibitors. Rao, Srinivas G.; Kranzler, Jay D. (Cypress Bioscience, Inc., USA). PCT Int. Appl. WO 2004009069 A1 29 Jan 2004, 33 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2.There are some reagents with their cas registry numbers 106650-56-0 and 50-67-9 are used in this study. CLASS: ICM: A61K031-165. APPLICATION: WO 2003-US23088 24 Jul 2003. PRIORITY: US 2002-PV398676 24 Jul 2002; US 2003-PV443035 28 Jan 2003. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) The invention discloses the methods for the prevention or treatment of atypical depression secondary to pain (DSP). The method generally involves administering an effective amt. of a monoamine re uptake inhibitor to treat or prevent symptoms of DSP. In a preferred embodiment, a therapeutically effective amt. of a dual serotonin norepinephrine reuptake inhibitor (SRNI) compd. of a specific type, or a pharmaceutically acceptable salt thereof is administered. The most preferred SNRI compds. are non-tricyclic SNRIs, wherein serotonin reuptake inhibition is greater than norepinephrine reuptake inhibition; and NSRIs, wherein norepinephrine reuptake inhibition is greater than serotonin reuptake inhibition. The most preferred compd. is milnacipran or a bioequivalent or pharmaceutically acceptable salt thereof. Other preferred compds. are duloxetine and venlafaxine or a bioequivalent or pharmaceutically acceptable salt thereof. In yet another embodiment, a therapeutically effective amt. of a non-tricyclic triple reuptake inhibitor ('TRI') compd. of a specific type, or a pharmaceutically acceptable sait thereof, is administered. The TRI compds. are characterized by their ability to block the reuptake (and, hence, increase central concns. of) the three primary brain monoamines: serotonin, noradrenaline, and dopamine. .